{"pub": "marketwatch", "url": "https://marketwatch.com/story/puma-biotech-stock-surges-on-fda-cancer-drug-designation-2019-09-03?mod=hp_investing", "downloaded_at": "2019-09-03 23:42:55.519787+00:00", "title": "Puma Biotech stock surges on FDA cancer drug designation", "language": "en", "published_at": "2019-09-03", "text": "Puma Biotechnology Inc. PBYI, -2.98% shares rallied in the extended session Tuesday after the drug developer said the Food and Drug Administration granted its cancer treatment a special designation. Puma shares rose 7.4% after hours, following a 3% decline to close the regular session at $10.43. The company said the FDA granted an \"orphan drug\" designation for its drug Nerlynx for the treatment of breast cancer patients with brain metastases. An orphan drug designation gives a drug maker incentives such as grant funding toward clinical trial costs and a possible seven years of market exclusivity to treat conditions that affect 200,000 people or less in the U.S.", "description": "Puma Biotechnology Inc. shares rallied in the extended session Tuesday after the drug developer said the Food and Drug Administration granted its cancer...", "authors": ["Wallace Witkowski"], "top_image": "https://mw3.wsj.net/mw5/content/logos/mw_logo_social.png"}